Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 18/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120068 | 0.95 | CCR2 (0.39) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13011667 | 0.95 | CCR2 (0.39) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13011668 | 0.95 | CCR2 (0.39) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL1119935 | 0.90 | CCR2 (0.39) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL1119949 | 0.90 | CCR2 (0.39) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL1119938 | 0.90 | CCR2 (0.39) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL1119320 | 0.90 | SLC6A9 (0.36) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13011569 | 0.90 | SLC6A9 (0.36) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL15353818 | 0.90 | KCNJ1 (0.32) | — | |
| SCHEMBL15353817 | 0.90 | KCNJ1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286136-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | JONES SIMON | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286136-A1 | DIHYDRONAPHTHYRIDINYL AND RELATED COMPOUNDS FOR USE IN TREATING OPHTHALMOLOGICAL DISORDERS | ALDH1A2, QDPR, PDE6C | CCR2 3022/4885CCR1 3651/4885TMEM97 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.